PMID- 22213863
OWN - NLM
STAT- MEDLINE
DCOM- 20120517
LR  - 20151119
IS  - 0253-2727 (Print)
IS  - 0253-2727 (Linking)
VI  - 32
IP  - 7
DP  - 2011 Jul
TI  - [Monitoring of plasma concentration of imatinib mesylate in patients with chronic 
      myeloid leukemia].
PG  - 450-3
AB  - OBJECTIVE: To analyze the clinical efficacy of imatinib mesylate (IM) for 
      Ph-positive or BCR-ABL positive chronic myeloid leukemia (CML) to couple the 
      trough plasma concentrations (C mins) of IM with clinical responses and adverse 
      events (AEs). METHODS: One hundred and one CML patients received IM therapy, and 
      Cmins of IM were determined in 30 patients. RESULTS: (1) Cumulative complete 
      hematological response (CHR), major cytogenetic response (MCyR), complete 
      cytogenetic response (CCyR) and negative BCR/ABL fusion gene rates were 96.6%, 
      86.5%, 77.5% and 47.2%, respectively, in CML-CP patients. In accelerated and 
      blastic phases (AP and BC) patients, CHR, MCyR, CCyR and negative BCR-ABL fusion 
      gene rates were 58.3%, 25.0%, 25.0%, 8.3%, respectively. (2) Mean Cmins of IM was 
      significantly higher in the CCyR at 1 year [(1472 +/- 482) microg/L] group than 
      in the non-CCyR at 1 years group [(1067 +/- 373) microg/L] (P < 0.05), and higher 
      in the MMR at 1 year group than in the non-MMR at 1 years group [(1624 +/- 468) 
      microg/L vs (1137 +/- 404) microg/L, P < 0.05]. CONCLUSION: IM significantly 
      improves cytogenetic and molecular response, event-free survival, and overall 
      survival for patients with Ph-positive CML. The Cmins of IM exerts a significant 
      impact on clinical response (CCyR and MMR at 1 year).
FAU - Chen, Chen
AU  - Chen C
AD  - Department of Hematology, Qilu Hospital of Shandong University, Jinan 250012, 
      China.
FAU - Wang, Wen
AU  - Wang W
FAU - Xu, Cong-Gao
AU  - Xu CG
FAU - Hou, Ming
AU  - Hou M
FAU - Wang, Lu-Qun
AU  - Wang LQ
FAU - Liu, Chuan-Fang
AU  - Liu CF
FAU - Song, Qiang
AU  - Song Q
FAU - Ji, Chun-Yan
AU  - Ji CY
LA  - chi
PT  - Clinical Trial
PT  - English Abstract
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - China
TA  - Zhonghua Xue Ye Xue Za Zhi
JT  - Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
JID - 8212398
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Benzamides)
RN  - 0 (Piperazines)
RN  - 0 (Pyrimidines)
RN  - 8A1O1M485B (Imatinib Mesylate)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Antineoplastic Agents/blood/*therapeutic use
MH  - Benzamides
MH  - Female
MH  - Humans
MH  - Imatinib Mesylate
MH  - Leukemia, Myelogenous, Chronic, BCR-ABL Positive/*blood/*drug therapy
MH  - Male
MH  - Middle Aged
MH  - Piperazines/blood/*therapeutic use
MH  - Pyrimidines/blood/*therapeutic use
MH  - Treatment Outcome
MH  - Young Adult
EDAT- 2012/01/04 06:00
MHDA- 2012/05/18 06:00
CRDT- 2012/01/04 06:00
PHST- 2012/01/04 06:00 [entrez]
PHST- 2012/01/04 06:00 [pubmed]
PHST- 2012/05/18 06:00 [medline]
PST - ppublish
SO  - Zhonghua Xue Ye Xue Za Zhi. 2011 Jul;32(7):450-3.